April 16, 2018
WELLESLEY, Mass., April 16, 2018– Increasing government incentives and support, rising investments in research and development, and an expanding aged population are driving growth in the urinary incontinence and overactive bladder drug market. In a new report, Drugs for Urinary Incontinence and Overactive Bladder: Global Markets to 2022, BCC Research estimates this market to reach $4.2 billion by 2022, up from $3.6 billion in 2017, indicating a compound annual growth rate (CAGR) of 2.9%.
Technological advances in clinical research combined with favorable health care reforms and the expanding research and development efforts of drug companies are also pushing market growth. The market will be challenged by restraints such as a decline in drug patent expirations, rising popularity of alternative treatments and therapies, social stigmas associated with the disease, and lack of awareness in many global countries.
Overall, the global urinary incontinence and overactive bladder market growth demonstrates significant growth potential. Many factors are conspiring to bring market growth, in particular advances in drug development. Mainly, site-specific local drug delivery, lower side effects, different forms of medications and combination therapy are major market trends. Among global regions, Asia-Pacific is the largest market for urinary incontinence and overactive bladder drugs, totaling 35.2% of the global market, followed by North America and Western Europe. Asia-Pacific is expected to achieve the highest CAGR, at 4.0%, followed by Africa’s 3.4% CAGR. Regarding value, the United States is the largest market. Among countries, China and India are forecasted to grow the fastest, achieving a CAGR of 10.1% and 9.7%, respectively.
“Companies in the drugs for urinary incontinence and overactive bladder market are continuously investing in R&D activities to expand drug product line and increase their share in the market,” said Robert G. Hunter, BCC Research senior editor, healthcare. “There are several drugs for urinary incontinence and overactive bladder in phase III clinical trials, and going forward, a new class of drugs is expected to drive the market.”
Editors/reporters requesting analyst interviews should contact email@example.com.
Drugs for Urinary Incontinence and Overactive Bladder: Global Markets to 2022( PHM199A )
Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email firstname.lastname@example.org or visit www.bccresearch.com/media to request access to our library of market research.